Browse by Series:

Full FDA Approvals in Breast Cancer and Lung Cancer, Priority Reviews in ALL, and More

Brielle Urciuoli
Published: Thursday, Apr 06, 2017



Brielle Urciuoli reports on full FDA approvals in breast cancer and non–small cell lung cancer, priority reviews in acute lymphoblastic leukemia, an ODAC recommendation for hematologic malignancies, a biologics license application submitted in non–Hodgkin lymphoma, a new drug application accepted in graft-versus-host disease, promising phase III results and a European approval in lung cancer.
SELECTED
LANGUAGE
Slider Left
Slider Right


Brielle Urciuoli reports on full FDA approvals in breast cancer and non–small cell lung cancer, priority reviews in acute lymphoblastic leukemia, an ODAC recommendation for hematologic malignancies, a biologics license application submitted in non–Hodgkin lymphoma, a new drug application accepted in graft-versus-host disease, promising phase III results and a European approval in lung cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x